Published in J Infect Dis on July 06, 2000
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. Cell Host Microbe (2015) 2.98
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 2.03
Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol (2007) 1.71
Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol (2009) 1.19
Ontogeny and specificities of mucosal and blood human immunodeficiency virus type 1-specific CD8(+) cytotoxic T lymphocytes. J Virol (2003) 1.14
Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One (2009) 1.11
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother (2011) 1.04
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother (2009) 1.01
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol (2001) 0.97
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet (2012) 0.91
Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time. J Infect Dis (2013) 0.91
Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. Virology (2009) 0.90
Small ruminant lentiviruses: genetic variability, tropism and diagnosis. Viruses (2013) 0.87
Comparison of washing and swabbing procedures for collecting genital fluids to assess cervicovaginal shedding of herpes simplex virus type 2 DNA. J Clin Microbiol (2003) 0.86
Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in cell-free cervicovaginal secretions: comparison of reverse transcription-PCR amplification (AMPLICOR HIV-A MONITOR 1.5) with enhanced-sensitivity branched-DNA assay (Quantiplex 3.0). J Clin Microbiol (2001) 0.85
HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077. PLoS One (2014) 0.84
Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission. Clin Perinatol (2010) 0.82
Study of compartmentalization in the visna clinical form of small ruminant lentivirus infection in sheep. BMC Vet Res (2012) 0.81
Comparison of washing and swabbing procedures for collecting genital fluids to assess shedding of human immunodeficiency virus type 1 (HIV-1) RNA in asymptomatic HIV-1-infected women. J Clin Microbiol (2003) 0.81
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. Antimicrob Agents Chemother (2012) 0.81
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother (2004) 0.80
Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.79
German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. Eur J Med Res (2009) 0.78
Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2. Clin Diagn Lab Immunol (2003) 0.77
Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives. J Exp Pharmacol (2013) 0.76
HIV migration between blood plasma and cellular subsets before and after HIV therapy. J Med Virol (2015) 0.75
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women. J Acquir Immune Defic Syndr (2015) 0.75
Novel methodology for antiretroviral quantitation in the female genital tract. HIV Clin Trials (2009) 0.75
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
A computer network for the surveillance of communicable diseases: the French experiment. Am J Public Health (1986) 5.38
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet (1997) 4.77
Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia. J Infect Dis (1985) 4.52
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother (1996) 4.04
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors. Antimicrob Agents Chemother (1988) 3.57
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis (2000) 3.21
Mediastinitis due to multiple resistant Corynebacterium xerosis. Clin Infect Dis (1993) 3.14
Natural autoantibodies. Curr Opin Immunol (1995) 3.00
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
Use of penicillin-binding proteins for the identification of enterococci. J Gen Microbiol (1986) 2.87
One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol (1985) 2.73
Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob Agents Chemother (1990) 2.70
Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother (1991) 2.68
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother (1986) 2.63
Differences in sexual risk behaviour between young men and women travelling abroad from the UK. Lancet (1998) 2.52
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 2.50
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother (1991) 2.35
In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis (1989) 2.27
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17
Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol (1998) 2.16
Susceptibility of Nocardia asteroides to 46 antibiotics, including 22 beta-lactams. Antimicrob Agents Chemother (1983) 2.15
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother (1994) 2.13
Nucleotide sequence of the SHV-5 beta-lactamase gene of a Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother (1990) 2.08
Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J Bacteriol (1996) 2.08
Comparison of vancomycin-inducible proteins from four strains of Enterococci. FEMS Microbiol Lett (1990) 2.01
Natural conception in HIV-negative women with HIV-infected partners. Lancet (1997) 1.98
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol (2001) 1.97
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS (2000) 1.97
Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol (1985) 1.91
Experimental production of antibodies against stratum corneum keratin polypeptides. Arch Dermatol Res (1980) 1.87
Presence of an additional penicillin-binding protein in methicillin-resistant Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus simulans with a low affinity for methicillin, cephalothin, and cefamandole. Antimicrob Agents Chemother (1990) 1.83
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 1.81
Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant (1994) 1.80
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis (2001) 1.76
Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother (1990) 1.75
Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis (1995) 1.74
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother (1993) 1.73
In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol (1997) 1.69
Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med (2008) 1.63
Pupil-sparing oculomotor nerve palsy due to midbrain infarction. Arch Neurol (1991) 1.63
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (1998) 1.62
Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood (1996) 1.62
Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J Biol Chem (2000) 1.62
A new approach to combatting iodine deficiency in developing countries: the controlled release of iodine in water by a silicone elastomer. Am J Public Health (1993) 1.58
Molecular evolution of ubiquitous beta-lactamases towards extended-spectrum enzymes active against newer beta-lactam antibiotics. Mol Microbiol (1990) 1.55
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol (2000) 1.53
Epidemiology of infective endophthalmitis in France. The French Collaborative Study Group on Endophthalmitis. Lancet (1991) 1.53
Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother (2001) 1.52
In vitro inactivation of Chlamydia trachomatis and of a panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the spermicide benzalkonium chloride. J Antimicrob Chemother (2000) 1.52
Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob Agents Chemother (1991) 1.52
Neuropathy in diffuse infiltrative lymphocytosis syndrome: an HIV neuropathy, not a lymphoma. Neurology (1998) 1.51
Characterization of nutritionally variant streptococci by biochemical tests and penicillin-binding proteins. J Clin Microbiol (1985) 1.51
Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS (1999) 1.51
Characterization of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals. Vigil'Roc Study Group. J Antimicrob Chemother (1993) 1.50
Analysis of peptidoglycan precursors in vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.50
Skin diseases associated with the cosmetic use of bleaching products in women from Dakar, Senegal. Br J Dermatol (2003) 1.50
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A (1987) 1.49
Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis (1998) 1.48
Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol (2000) 1.48
Metabolic derepression of alpha-amylase gene expression in suspension-cultured cells of rice. J Biol Chem (1991) 1.48
Atypical deep peroneal neuropathy in presence of accessory deep peroneal nerve. J Neurol Neurosurg Psychiatry (1970) 1.47
In-vitro susceptibility of Nocardia asteroides to 21 beta-lactam antibiotics, in combination with three beta-lactamase inhibitors, and its relationship to the beta-lactamase content. J Antimicrob Chemother (1985) 1.46
The new quinolones and their combinations with other agents for therapy of severe infections. J Antimicrob Chemother (1986) 1.46
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase. Antimicrob Agents Chemother (1990) 1.45
Comparative assessment of five alternative methods for CD4+ T-lymphocyte enumeration for implementation in developing countries. J Acquir Immune Defic Syndr (2001) 1.44
Picornavirus-like crystals in subacute polymyositis. Neurology (1970) 1.44
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.43
When is myokymia neuromyotonia? Muscle Nerve (2001) 1.43
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum (2001) 1.43
Fatal acute haemolysis in an AIDS patient treated with indinavir. AIDS (1998) 1.43
Electrodiagnosis of infantile botulism. J Child Neurol (1994) 1.41
Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods (1998) 1.41
Mechanisms of resistance to quinolones. Drugs (1993) 1.41
Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry (1998) 1.41
Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis (1995) 1.40
Pick's disease: a case clinically resembling amyotrophic lateral sclerosis. Neurology (1991) 1.40
Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother (2013) 1.40
Persistent unilateral tibialis anterior muscle hypertrophy with complex repetitive discharges and myalgia: report of two unique cases and response to botulinum toxin. Neurology (1992) 1.39
AIDS-related Stomatococcus mucilaginosus infection. Lancet (1991) 1.39
Hematogeneous osteitis due to Yersinia enterocolitica. J Infect Dis (1989) 1.39
Intrapontine generation of myokymia in multiple sclerosis. Muscle Nerve (1993) 1.39
Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J Immunol (1991) 1.39
Sch 34343 activity against streptococci and beta-lactam-resistant Enterobacteriaceae. J Antimicrob Chemother (1985) 1.39
Guillain-Barre syndrome. Another immune-mediated disease with a predilection for young women? W V Med J (1989) 1.38
Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect (2006) 1.38
Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care (2003) 1.38
Amnesia due to fornix infarction. Stroke (2000) 1.37
Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol (1991) 1.37
Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1991) 1.37